Argobio is a start-up studio based in Paris, France, dedicated to turning cutting-edge innovations into breakthrough biotech companies.
Argobio sources innovative early-stage projects on therapeutics from renowned European academic research institutions with a focus on rare diseases, neurological disorders, oncology and immunology. The studio selects and incubates these projects with the goal to create biotech companies and develop them up to a significant Series A financing.
Argobio provides broad expertise in the discovery and development of novel drugs with a team of highly experienced Biotech entrepreneurs. The internal team is led by Yves Ribeill, Neill Mackenzie and Rémi Soula. Thierry Laugel, Managing Partner at Kurma Partners is the President of Argobio.
Accelerate in-licensed projects
up to company creation
and venture funding
Exceptionnal academic projects
from European universities
Therapeutics
rare diseases, neurosciences,
oncology, immunology
€50 M to build
high potential companies
over the next years
Dedicated and experienced team
with entreprenarial
track-record
Company based in Paris
Launched in March 2021
Virtual organization
Argobio was initiated by Kurma Partners, a leading Paris-based healthcare venture capital firm, and Bpifrance, the French national investment bank. Kurma and Bpifrance were joined by complementary strategic investors, Angelini Pharma, a private international pharmaceutical company, Evotec, a drug discovery alliance and development partnership company, and the Institut Pasteur, internationally renowned center for biomedical research.
ArgoBio and Oncode Institute have teamed up with Oncode Investigator Madelon Maurice, researcher and group leader at UMC Utrecht, to launch Laigo Bio, a new company in the emerging field of target protein degradation.
Argobio and GeneCode have announced their collaboration to develop small molecule Glial cell line - Derived Neurotrophic Factor (GDNF) mimetics for the treatment of Parkinson’s …
Argobio is led by a highly experienced group of biotech Entrepreneurs in Residence, experts in biotechnologies, who will identify innovative technologies from European …